Introduction to the benefits and possible risks of using Platinib (Pujihua)

Pralsetinib is a selective RETkinase inhibitor, mainly used to treat patients with RET fusion or mutation-positive non-small cell lung cancer (NSCLC), thyroid cancer and other solid tumors. Its biggest advantage is its precise targeting, which can effectively block RET-driven tumor growth signals, thereby significantly delaying disease progression. Clinical studies have shown that RETpositive patients have significantly improved progression-free survival (PFS) and objective response rate (ORR) after using platinib. Compared with traditional chemotherapy regimens, the efficacy is more significant and the quality of life of patients can be improved.

Another advantage of Platinib is that it is convenient for oral administration. Patients can take the medicine at home as directed by the doctor, without the need for frequent intravenous infusion in the hospital, reducing the burden of medical treatment. In addition, it has strong targeting ability, theoretically has less impact on non-tumor cells, and has good overall tolerance. Most patients are able to maintain efficacy during long-term treatment without affecting their activities of daily living. Platinib provides a new treatment option for RET-positive patients who have received multiple treatments but still have tumor progression.

However, platinib also has certain risks. Common adverse reactions include hematological abnormalities (such as neutropenia, thrombocytopenia), abnormal liver function, hypertension, fatigue, diarrhea and rash. Most adverse reactions are mild to moderate and can be alleviated through dose adjustment or symptomatic treatment, but they still need to be used under the guidance of a professional doctor. Although serious adverse reactions are rare, once they occur, they may affect the safety of treatment, so blood routine, liver function and cardiovascular indicators need to be monitored regularly during use.

In addition, the drug interactions of platinib also require special attention. Concomitant use with strong CYP3A inhibitors or inducers may lead to abnormal plasma concentrations, thereby affecting efficacy or increasing the risk of adverse reactions. During the medication period, patients should truthfully inform the doctor of all medications they are taking, including Chinese herbal medicines and health care products, so that the treatment plan can be adjusted. In general, platinib has significant advantages in targeting RET-driven tumors, but rational use, regular monitoring and attention to drug interactions are the keys to ensuring safety and efficacy.

Reference link:https://www.drugs.com